News
![FDA warns of genital gangrene risk with diabetes drug class](/sites/default/files/styles/x_large/public/default_images/empty.jpg?itok=C-Mgnvzj)
FDA warns of genital gangrene risk with diabetes drug class
The US regulator released an official risk warning of a rare genital infection identified in 12 patients, including one fatality, after using SGLT2 class drugs for type 2 diabetes.